The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study.

Meng-Jia SongQiu-Zhong PanYa DingJianxiong ZengPei DongJing-Jing ZhaoYan TangJingjing LiZhiling ZhangJunyi HeJieying YangYue HuangRuiqing PengQi-Jing WangJia-Mei GuJia HeYong-Qiang LiShi-Ping ChenRongxing HuangZi-Qi ZhouChaopin YangYulong HanHao ChenHeping LiuShangzhou XiaYang WanDe-Sheng WengLiming XiaFang-Jian ZhouJian-Chuan Xia

Published in: Clinical & translational immunology (2021)

The combination therapy was active and well tolerated for treatment of advanced RCC, either as first- or second-line treatment following other targeted agents. Changes in immunophenotype and serum cytokine profile may be used as prognostic biomarkers.

Keyphrases

combination therapy
renal cell carcinoma
randomized controlled trial
stem cells
bone marrow
clinical trial
immune response
advanced non small cell lung cancer
cancer therapy
epidermal growth factor receptor
smoking cessation